BioVentrix Expands Life-Extending Transcatheter Heart Failure Treatment To Second European Clinical Site

Published: Dec 12, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN RAMON, Calif. & PRAGUE--(BUSINESS WIRE)--BioVentrix, a pioneer of technologies and procedures for less-invasive treatment of heart failure (HF), today announced that placement of its Revivent-TC™ Ventricular Enhancement System, via Less Invasive Ventricular Enhancement™ or the LIVE™ procedure, has been successfully expanded to a second European clinical site. The procedure, which is used to reshape and reduce the left ventricle (LV), was performed on a 64-year-old man suffering from ischemic heart failure. Performed by Prof. Petr Neuzil and Dr. Ivo Skalsky at Na Holmoce Hospital in Prague, Czech Republic, the transcatheter procedure was performed without opening the patient’s chest and without the use of a heart-lung bypass machine.

Help employers find you! Check out all the jobs and post your resume.

Back to news